REGENERON PHARMACEUTICALS, INC.

REGN · CIK 0000872589

18 fiscal years · 65 SEC filings · every number carries its receipt

Revenue (FY)

$14.34B1.0%

FY2025

Net income (FY)

$4.50B2.1%

FY2025

Free cash flow (FY)

$4.08B11.3%

FY2025

Diluted EPS (FY)

$41.488.2%

FY2025

The story, charted

The shape of the business

FY2008–FY2025 · hover any year for its receipt

Revenue & net incomeRevenueNet income

revenue 60.1× since FY2008 · net margin -33.2% → 31.4%

MarginsNet marginFCF margin

FY2025: net 31.4% · free cash flow 28.4% of revenue

Cash engineOperating cash flowFree cash flow

FY2025: $4.98B operating cash − $898.4M capex = $4.08B free cash flow

Returns on capitalReturn on equityReturn on assets

return on equity -17% (FY2009) → 14% (FY2025) · on assets 11.1%

Balance sheetLiabilitiesEquity

FY2025: $40.56B assets · $9.30B liabilities · $31.26B equity

The receipts

Financial statements

Annual Quarterly (as reported)

USD in millions except per-share and share counts. Every value links to the filing it came from — hover for the us-gaap tag, click for the 10-K/10-Q on sec.gov.

USD millions	Q1 2026	Q3 2025	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022	Q2 2022
Revenue	3,605	3,754	3,676	3,029	3,721	3,547	3,145	3,363	3,158	3,162	2,936	2,857
Net income	727	1,460	1,392	809	1,341	1,432	722	1,008	968	818	1,316	852
Diluted EPS	6.75	13.62	12.81	7.27	11.54	12.41	6.27	8.89	8.50	7.17	11.66	7.47
Diluted shares	108	107	109	111	116	115	115	113	114	114	113	114
Operating cash flow	1,079	—	—	1,045	—	—	1,513	—	—	1,368	—	—
Capital expenditures	231	—	—	229	—	—	134	—	—	178	—	—
Free cash flow	848	—	—	816	—	—	1,379	—	—	1,189	—	—
Cash & equivalents	2,963	2,506	1,996	3,090	2,012	1,921	2,602	2,152	1,937	3,916	3,491	3,395
Total assets	40,869	40,169	38,219	37,545	37,442	36,087	34,370	32,163	30,658	30,060	27,678	27,206
Total liabilities	9,445	9,212	8,280	8,158	8,116	7,881	7,379	7,259	6,640	6,565	6,239	6,518
Shareholders' equity	31,424	30,958	29,939	29,388	29,326	28,206	26,991	24,904	24,018	23,495	21,439	20,688

Figures as reported in SEC filings, normalized by stonks with the tag mapping shown on hover; missing tags render as “—”, never as zero. Free cash flow is derived (operating cash flow − capex) with both parents recorded in its lineage. Quarterly view shows as-reported 10-Q periods; Q4 synthesis ships in Phase 1. See methodology.